Patients receiving ELITEK® should be for potential hypersensitivity reactions, including anaphylaxis. 

Warnings and Cautions

Immediate discontinuation is required if a serious reaction occurs. The drug should not be used in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the risk of hemolysis, which could be fatal. Additionally, methemoglobinemia may occur, necessitating discontinuation of treatment. Blood samples for uric acid should be handled correctly, as ELITEK® interferes with uric acid measurements by degrading it in blood samples left at room temperature.